Dr. He attended Central South University Xiang-Ya School of Medicine in China, graduating with a Bachelor of Medicine in 2003. He went on to earn a PhD in clinical pharmacology from Central South University in China and Ulm University in Germany jointly in 2008 under the supervision of Professor Hong-Hao Zhou. Thereafter, he continued his research endeavours at University of North Carolina Eshelman School of Pharmacy in the Center for Pharmacogenomics and Individualized Therapy, and Gentris Corporation in the United States from 2009 to 2012.

Upon his return to China in 2013, Dr. He served as Deputy Director of Engineering Research Center for Pharmacogenomics at the Ministry of Education in Central South University. He has published more than 50 SCI papers with impact factor exceeding 10 and over 200 citations.

He presided over 10 research projects with funding support by the National Natural Science Foundation of China, the Hunan Province University Open Innovation Platform Fund, the Hunan Provincial Youth Program and Changsha 3635 Talent Project to name a few.

He presided over 10 research projects with funding support by the National Natural Science Foundation of China, the Hunan Province University Open Innovation Platform Fund, the Hunan Provincial Youth Program and Changsha 3635 Talent Project to name a few.

He founded and became Managing Director in Asia at Interpares Biomedical Co. Ltd. in the United States in 2015. He is presently Chairman and Chief Scientist at Shenzhen INDA Biomedical Co. Ltd, a company he founded in 2016 and excelling in the area of clinical companion diagnostics for tumor immunotherapy.